PPLPHARMA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 21/100 — Quality 24 · Growth 28 · Momentum 0
| Share price | ₹178.87 |
| Market cap | ₹20,673 Cr |
| P/B ratio | 2.6 |
| ROE | -24.6% |
| ROCE | 1.2% |
| Dividend yield | 0.09% |
| Book value | ₹61.03 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹8,869 Cr | ₹-326 Cr | 10.0% |
| 2025 | ₹9,151 Cr | ₹91 Cr | 16.0% |
| 2024 | ₹8,171 Cr | ₹18 Cr | 15.0% |
| 2023 | ₹7,082 Cr | ₹-186 Cr | 9.0% |
| 2022 | ₹6,559 Cr | ₹376 Cr | 14.0% |
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generi